Ken Mariash, CEO of Sinaptica Therapeutics, talks with EisnerAmper's TechTalk host Janina Teoxon about the novel approach his startup is taking to develop a non-drug therapy to treat Alzheimer's. In this episode, Ken acknowledges the repeated failures the industry has faced on its quest to find a cure for the disease and explains why his personalized and connectome-targeted neuromodulation approach has gained the FDA breakthrough designation. Learn how Ken and his team are overcoming investor skepticism as their promising treatment emerges.
Create your
podcast in
minutes
It is Free